Driven By Purpose
Patients with psychiatric and neurological disorders deserve better treatments. At Xylo, we are developing innovative, mechanism-based therapies to provide effective solutions for these complex conditions. By redefining care, we aim to address critical unmet needs and create lasting impact for patients and healthcare systems.
Our Story
Founded in 2021 as Psylo, we began by pioneering psychedelic-inspired drug discovery through computational and rational drug design. As our vision and technology evolved, so did our focus.
In 2025, the company rebranded as Xylo Bio to emphasize our core expertise in neuroscience and neuroplastogens. This evolution reflects our commitment to delivering innovative, accessible therapies and positions us for the next phase of growth as we expand our pipeline and advance clinical development.
Xylo marks the next bold step in our journey to redefine treatments for complex psychiatric and neurological disorders. With a focus on optimized, targeted therapies, we are shaping the next generation of treatments to improve the lives of patients worldwide.
Read more about Psylo’s founding in Cosmos Magazine.
Investors
.webp)